Skip to main content

Solithromycin in Children and Adolescents With Community-acquired Bacterial Pneumonia.

Publication ,  Journal Article
Lang, JE; Hornik, CP; Elliott, C; Silverstein, A; Hornik, C; Al-Uzri, A; Bosheva, M; Bradley, JS; Borja-Tabora, CFC; Di John, D; Ericson, JE ...
Published in: Pediatr Infect Dis J
July 1, 2022

BACKGROUND: Solithromycin is a new macrolide-ketolide antibiotic with potential effectiveness in pediatric community-acquired bacterial pneumonia (CABP). Our objective was to evaluate its safety and effectiveness in children with CABP. METHODS: This phase 2/3, randomized, open-label, active-control, multicenter study randomly assigned solithromycin (capsules, suspension or intravenous) or an appropriate comparator antibiotic in a 3:1 ratio (planned n = 400) to children 2 months to 17 years of age with CABP. Primary safety endpoints included treatment-emergent adverse events (AEs) and AE-related drug discontinuations. Secondary effectiveness endpoints included clinical improvement following treatment without additional antimicrobial therapy. RESULTS: Unrelated to safety, the sponsor stopped the trial prior to completion. Before discontinuation, 97 participants were randomly assigned to solithromycin (n = 73) or comparator (n = 24). There were 24 participants (34%, 95% CI, 23%-47%) with a treatment-emergent AE in the solithromycin group and 7 (29%, 95% CI, 13%-51%) in the comparator group. Infusion site pain and elevated liver enzymes were the most common related AEs with solithromycin. Study drug was discontinued due to AEs in 3 subjects (4.3%) in the solithromycin group and 1 (4.2%) in the comparator group. Forty participants (65%, 95% CI, 51%-76%) in the solithromycin group achieved clinical improvement on the last day of treatment versus 17 (81%, 95% CI, 58%-95%) in the comparator group. The proportion achieving clinical cure was 60% (95% CI, 47%-72%) and 68% (95% CI, 43%-87%) for the solithromycin and comparator groups, respectively. CONCLUSIONS: Intravenous and oral solithromycin were generally well-tolerated and associated with clinical improvement in the majority of participants treated for CABP.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pediatr Infect Dis J

DOI

EISSN

1532-0987

Publication Date

July 1, 2022

Volume

41

Issue

7

Start / End Page

556 / 562

Location

United States

Related Subject Headings

  • Triazoles
  • Pneumonia, Bacterial
  • Pediatrics
  • Macrolides
  • Humans
  • Community-Acquired Infections
  • Child
  • Anti-Bacterial Agents
  • Adolescent
  • 3213 Paediatrics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lang, J. E., Hornik, C. P., Elliott, C., Silverstein, A., Hornik, C., Al-Uzri, A., … SOLI-PEDS Program, . (2022). Solithromycin in Children and Adolescents With Community-acquired Bacterial Pneumonia. Pediatr Infect Dis J, 41(7), 556–562. https://doi.org/10.1097/INF.0000000000003559
Lang, Jason E., Christoph P. Hornik, Carrie Elliott, Adam Silverstein, Chi Hornik, Amira Al-Uzri, Miroslava Bosheva, et al. “Solithromycin in Children and Adolescents With Community-acquired Bacterial Pneumonia.Pediatr Infect Dis J 41, no. 7 (July 1, 2022): 556–62. https://doi.org/10.1097/INF.0000000000003559.
Lang JE, Hornik CP, Elliott C, Silverstein A, Hornik C, Al-Uzri A, et al. Solithromycin in Children and Adolescents With Community-acquired Bacterial Pneumonia. Pediatr Infect Dis J. 2022 Jul 1;41(7):556–62.
Lang, Jason E., et al. “Solithromycin in Children and Adolescents With Community-acquired Bacterial Pneumonia.Pediatr Infect Dis J, vol. 41, no. 7, July 2022, pp. 556–62. Pubmed, doi:10.1097/INF.0000000000003559.
Lang JE, Hornik CP, Elliott C, Silverstein A, Hornik C, Al-Uzri A, Bosheva M, Bradley JS, Borja-Tabora CFC, Di John D, Mendez Echevarria A, Ericson JE, Friedel D, Gonczi F, Isidro MGD, James LP, Kalocsai K, Koutroulis I, Laki I, Ong-Lim ALT, Nad M, Simon G, Syed S, Szabo E, Benjamin DK, Cohen-Wolkowiez M, SOLI-PEDS Program. Solithromycin in Children and Adolescents With Community-acquired Bacterial Pneumonia. Pediatr Infect Dis J. 2022 Jul 1;41(7):556–562.

Published In

Pediatr Infect Dis J

DOI

EISSN

1532-0987

Publication Date

July 1, 2022

Volume

41

Issue

7

Start / End Page

556 / 562

Location

United States

Related Subject Headings

  • Triazoles
  • Pneumonia, Bacterial
  • Pediatrics
  • Macrolides
  • Humans
  • Community-Acquired Infections
  • Child
  • Anti-Bacterial Agents
  • Adolescent
  • 3213 Paediatrics